Protein kinase C (PKC) involved in enhancement of α1-adrenoceptor-mediated responses of the main pulmonary artery in rats with diabetes mellitus
Abstract
Diabetes mellitus (DM) causes multiple dysfunctions including circulatory disorders such as cardiomyopathy, angiopathy, atherosclerosis and arterial hypertension. Moreover, DM can strongly affect pulmonary circulation, enhancing the wall thickness of the pulmonary arteries, changing their tone and contractility, and gas exchange in the lungs. It can lead to marked loss of lung function and respiratory efficiency. It is also known that protein kinase C (PKC) activity increases in DM and that PKC is involved in the mechanisms of DM-associated vascular complications. However, the effect of DM on pulmonary artery tone has been poorly investigated and the role of PKC in this remains unknown. The aim of this study was to investigate changes in contractility of pulmonary arteries in rats with DM and to determine the possible role of PKC in this process. Experimental type 1 DM was elicited in male Wistar rats by single streptozotocin (STZ, 65 mg/kg) injection. DM was verified by the presence of hyperglycaemia. The investigation was performed on the isolated rings of the main pulmonary arteries using the method of vascular tone registration. Phenylephrine (PhE, 0.1 nM – 1 mM) caused dose-dependent constriction of the pulmonary arteries. The pD2 (negative logarithm of the agonist concentration required for half-maximum response) of this constriction increased in rats with DM, however significant changes in amplitude of PhE-induced constriction were not observed. PKC inhibition with chelerythrine and staurosporine (1 µM) significantly shifted PhE the concentration-response curve to the right in intact diabetic vessels but had no effect on sensitivity to PhE in deendothelised diabetic vessels. Our data suggest that type 1 DM leads to enhancement in pulmonary artery α1-adrenoceptor-mediated contractility and PKC activity in the endothelium rather than in vascular SMCs is involved in this process.References
Abebe, W., & McLeod, K. M. (1991). Enhanced arterial contractility to noradrenaline in diabetic rats is associated with increased phosphoinositide metabolism. Canadian Journal of Physiology and Pharmacology, 49, 355–361.
Aljofan, M., & Ding, H. (2010). High glucose increases expression of cyclooxygenase-2, increases oxidative stress and decreases the generation of nitric oxide in mouse microvessel endothelial cells. Journal of Cellular Physiology, 222, 669–675.
Beckman, J. A., Goldfine, A. B., Gordon, M. B., Garrett, L. A., & Creager, M. A. (2002). Inhibition of protein kinase C beta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circulation Research, 90, 107–111.
Bohlen, H. G., & Nase, G. P. (2001). Arteriolar nitric oxide concentration is decreased during hyperglycemia-induced betaII PKC activation. American Journal of Physiology. Heart and Circulatory Physiology, 280, H621–627.
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011). Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. British Medical Journal, 343, d4169.
Brisset, A. C., Isakson, B. E., & Kwak, B. R. (2009). Connexins in vascular physiology and pathology. Antioxidants and Redox Signaling, 11, 267–282.
Chang, K. S. K., & Stevens, W. C. (1992). Endothelium-dependent increase in vascular sensitivity to phenylephrine in long-term streptozotocin diabetic rat aorta. British Journal of Pharmacology, 107, 983–990.
Chen, W. G., Zhu, X. F., Hou, J. Q., Pu, J. X., & Yan, C. Y. (2008). Expressions of eNOS and connexin 43 in the penile tissue of rats with diabetic erectile dysfunction. Zhonghua Nan Ke Xue, 14, 427–430.
Chow, W. L., Zhang, L., & MacLeod, K. M. (2001). Noradrenaline-induced changes in intracellular Ca2+ and tension in mesenteric arteries from diabetic rats. British Journal of Pharmacology, 134, 179–187.
Clarke, M., & Dodson, P. M. (2007). PKC inhibition and diabetic microvascular complications. Best Practice and Research: Clinical Endocrinology and Metabolism, 21, 573–586.
Cosentino, F., Eto, M., De Paolis, P., van der Loo, B., Bachschmid, M., Ullrich, V., Kouroedov, A., Delli Gatti, C., Joch, H., Volpe, M., & Lüscher, T. F. (2003). High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation, 107, 1017–1023.
Cosentino-Gomes, D., Rocco-Machado, N., & Meyer-Fernandes, J. R. (2012). Cell signaling through protein kinase C oxidation and activation. International Journal of Molecular Sciences, 13, 10697–10721.
Cosson, E., Pham, I., Valensi, P., Pariès, J., Attali, J. R., & Nitenberg, A. (2006). Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries. Diabetes Care, 29, 107–112.
Feletou, M., & Vanhoutte, P. (2010). Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflügers Archiv – European Journal of Physiology, 459, 863–879.
Figueroa, X. F., & Duling, B. R. (2009). Gap junctions in the control of vascular function. Antioxidants and Redox Signaling, 11, 251–266.
Fleming, I., Fisslthaler, B., Dimmeler, S., Kemp, B. E., & Busse, R. (2001). Phosphorylation of Thr495 regulates Ca2+/calmodulin-dependent endothelial nitric oxide synthase activity. Circulation Research, 88, E68–75.
Funk, S. D., Yurdagul, Jr. A., & Orr, A. W. (2012). Hyperglycemia and endothelial dysfunction in atherosclerosis: Lessons from type 1 diabetes. International Journal of Vascular Medicine, 2012, 1–19.
Gao, X., Martinez-Lemus, L. A., & Zhang, C. (2011). Endothelium-derived hyperpolarizing factor and diabetes. World Journal of Cardiology, 3, 25–31.
Georgescu, A., Alexandru, N., Constantinescu, E., & Popov, D. (2006). Effect of gap junction uncoupler heptanol on resistance arteries reactivity in experimental models of diabetes, hyperlipemia and hyperlipemia-diabetes. Vascular Pharmacology, 44, 513–518.
Geraldes, P., & King, G. L. (2010). Activation of protein kinase C isoforms and its impact on diabetic complications. Circulation Research, 106, 1319–1331.
Gurney, A. M., & Howarth, F. C. (2009). Effects of streptozotocin-induced diabetes on the pharmacology of rat conduit and resistance intrapulmonary arteries. Cardiovascular Diabetology, 8, 1–10.
Hattori, Y., Kawasaki, H., & Kanno, M. (1999). Increased contractile responses to endothelin-1 and U46619 via a protein kinase C-mediated nifedipine-sensitive pathway in diabetic rat aorta. Research Communications in Molecular Pathology and Pharmacology, 104, 73–80.
Herbert, M., Augereau, J. M., Gleye, J., & Maffrand, J. P. (1990). Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochemical and Biophysical Research Communications, 172, 993–999.
Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., Skatchkov, M., Thaiss, F., Stahl, R. A., Warnholtz, A., Meinertz, T., Griendling, K., Harrison, D. G., Forstermann, U., & Munzel, T. (2001). Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circulation Research, 88, E14–22.
Hirata, K., Kuroda, R., Sakoda, T., Katayama, M., Inoue, N., Suematsu, M., Kawashima, S., & Yokoyama, M. (1995). Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension, 25, 180–185.
Hou, C. J., Tsai, C. H., Su, C. H., Wu, Y. J., Chen, S. J., Chiu, J. J., Shiao, M. S., & Yeh, H. I. (2008). Diabetes reduces aortic endothelial gap junctions in ApoE-deficient mice: simvastatin exacerbates the reduction. Journal of Histochemistry and Cytochemistry, 56, 745–752.
Inoguchi, T., Li, P., Umeda, F., Yu, H. Y., Kakimoto, M., Imamura, M., Aoki, T., Etoh, T., Hashimoto, T., Naruse, M., Sano, H., Utsumi, H., & Nawata, H. (2000). High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 49, 1939–1945.
Inoguchi, T., Ueda, F., Umeda, F., Yamashita, T., & Nawata, H. (1995). Inhibition of intercellular communication via gap junction in cultured aortic endothelial cells by elevated glucose and phorbol ester. Biochemical and Biophysical Research Communications, 208, 492–497.
Inoguchi, T., Yu, H. Y., Imamura, M., Kakimoto, M., Kuroki, T., Maruyama, T., & Nawata, H. (2001). Altered gap junction activity in cardiovascular tissues of diabetes. Medical Electron Microscopy, 34, 86–91.
Ishida, K., Matsumoto, T., Taguchi, K., Kamata, K., & Kobayashi, T. (2012). Protein kinase C delta contributes to increase in EP3 agonist-induced contraction in mesenteric arteries from type 2 diabetic Goto-Kakizaki rats. European Journal of Physiology, 463, 593–602.
Ishii, H., Jirousek, M. R., Koya, D., Takagi, C., Xia, P., Clermont, A., Bursell, S. E., Kern, T. S., Ballas, L. M., Heath, W. F., Stramm, L. E., Feener, E. P., & King, G. L. (1996). Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science, 272, 728–731.
Kalani, M. (2008). The importance of endothelin-1 for microvascular dysfunction in diabetes. Vascular Health and Risk Management, 4, 1061–1068.
Kizub, I. V., Klymenko, K. I., & Soloviev, A. I. (2014). Protein kinase C in enhanced vascular tone in diabetes mellitus. International Journal of Cardiology, 174, 230–242.
Kizub, I. V., Pavlova, O. O., Johnson, C. D., Soloviev, A. I., & Zholos, A. V. (2010). Rho kinase and protein kinase C involvement in vascular smooth muscle myofilament calcium sensitization in arteries from diabetic rats. British Journal of Pharmacology, 159, 1724–1731.
Klymenko, K. I., Novokhatska, T. V., Kizub, I. V., Parshikov, A. V., Dosenko, V. E., & Soloviev, A. I. (2014). PKC-δ isozyme gene silencing restores vascular function in diabetic rat. Journal of Basic and Clinical Physiology and Pharmacology, 27, 1–9.
Kolluru, G. K., Bir, S. C., & Kevil, C. G. (2012). Endothelial dysfunction and diabetes: Effects on angiogenesis, vascular remodeling, and wound healing. International Journal of Vascular Medicine., 2012, 1–30.
Kuroki, T., Inoguchi, T., Umeda, F., Ueda, F., & Nawata, H. (1998). High glucose induces alteration of gap junction permeability and phosphorylation of connexin-43 in cultured aortic smooth muscle cells. Diabetes, 47, 931–963.
Lee, J.-H., Bahk, J.-H., Park, S.-H., & Huh, J. (2011). The diabetes-induced functional and distributional changes of the alpha 1-adrenoceptor of the abdominal aorta and distal mesenteric artery from streptozotocin-induced diabetic rats. Korean Journal of Anesthesiology, 60, 272–281.
Leo, C. H., Hart, J. L., & Woodman, O. L. (2011). Impairment of both nitric oxide mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocininduced diabetes. British Journal of Pharmacology, 162, 365–377.
Li, A. F., & Roy, S. (2009). High glucose-induced downregulation of connexin 43 expression promotes apoptosis in microvascular endothelial cells. Investigative Ophthalmology and Visual Science, 50, 1400–1407.
Lin, D., & Takemoto, D. J. (2005). Oxidative activation of protein kinase Cgamma through the C1 domain: Effects on gap junctions. Journal of Biological Chemistry, 280, 13682–13693.
Lopez–Lopez, J. G., Moral-Sanz, J., Frazziano, G., Gomez-Villalobos, M. J., Flores-Hernandez, J., Monjaraz, E., Cogolludo, A., & Perez-Vizcaino, F. (2008). Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction. American journal of Physiology. Lung Cellular and Molecular, 295, L727–L732.
Madonna, R., & De Caterina, R. (2011). Cellular and molecular mechanisms of vascular injury in diabetes – part I: Pathways of vascular disease in diabetes. Vascular Pharmacology, 54, 68–74.
Makino, A., Platoshyn, O., Suarez, J., Yuan, J. X., & Dillmann, W. H. (2008). Downregulation of connexin40 is associated with coronary endothelial cell dysfunction in streptozotocin-induced diabetic mice. American Journal of Physiology. Cell Physiology, 295, C221–C230.
Matsubara, M., Hayashi, N., Jing, T., & Titani, K. (2003). Regulation of endothelial nitric oxide synthase by protein kinase C. Journal of Biochemistry, 133, 773–781.
Matsumoto, T., Ishida, K., Nakayama, N., Kobayashi, T., & Kamata, K. (2009). Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. American Journal of Physiology. Heart and Circulatory Physiology, 296, H1388–1397.
Matsumoto, T., Kobayashi, T., & Kamata, K. (2006). Mechanisms underlying the impaired EDHF type relaxation response in mesenteric arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) rats. European Journal of Pharmacology, 538, 132–140.
Mehta, N. N., Sheetz, M., Price, K., Comiskey, L., Amrutia, S., Iqbal, N., Mohler, E. R., & Reilly, M. P. (2009). Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovascular Drugs and Therapy, 23, 17–24.
Michell, B. J., Chen, Z. P., Tiganis, T., Stapleton, D., Katsis, F., Power, D. A., Sim, A. T., & Kemp, B. E. (2001). Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein pinase. Journal of Biological Chemistry, 276, 17625–17658.
Mueed, I., Zhang, L., & MacLeod, K. M. (2005). Role of the PKC/CPI-17 pathway in enhanced contractile responses of mesenteric arteries from diabetic rats to a-adrenoceptor stimulation. British Journal of Pharmacology, 146, 972–982.
Nobe, K., Sakai, Y., Nobe, H., & Momose, K. (2003). Dysfunction of aorta involves different patterns of intracellular signalingpathways in diabetic rats. European Journal of Pharmacology, 471, 195–204.
Oku, H., Kodama, T., Sakagami, K., & Puro, D. G. (2001). Diabetes-induced disruption of gap junction pathways within the retinal microvasculature. Investigative Ophthalmology and Visual Science, 42, 1915–1920.
Park, J. Y., Takahara, N., Gabriele, A., Chou, E., Naruse, K., Suzuma, K., Yamauchi, T., Ha, S. W., Meier, M., Rhodes, C. J., & King, G. L. (2000). Induction of endothelin-1 expression by glucose: An effect of protein kinase C activation. Diabetes, 49, 1239–1248.
Pitocco, D., Zaccardi, F., Di Stasio, E., Romitelli, F., Santini, S. A., Zuppi, C., & Ghirlanda, G. (2010). Oxidative stress, nitric oxide, and diabetes. Review of Diabetic Studies, 7, 15–25.
Ramana, K. V., Friedrich, B., Tammali, R., West, M. B., Bhatnagar, A., & Srivastava, S. K. (2005), Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes, 54, 818–829.
Sato, T., Haimovici, R., Kao, R., Li, A. F., & Roy, S. (2002). Downregulation of connexin 43 expression by high glucose reduces gap junction activity in microvascular endothelial cells. Diabetes, 51, 1565–1571.
Somlyo, A. P., & Somlyo, A. V. (2003). Ca2+ sensitivity of smooth muscleand nonmuscle myosin II: Modulated by G proteins, kinases, and myosin phosphatase. Physiological Reviews, 83, 1325–1358.
Suzuma, K., Takahara, N., Suzuma, I., Isshiki, K., Ueki, K., Leitges, M., Aiello, L. P., & King, G. L. (2002). Characterization of protein kinase C beta isoform’s action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proceedings of the National Academy of Sciences of the United States of America, 99, 721–726.
Tickerhoof, M. M., Farrell, P. A., & Korzick, D. H. (2003). Alterations in rat coronary vasoreactivity and vascular protein kinase C isoforms in Type 1 diabetes. American Journal of Physiology. Heart and Circulatory Physiology, 285, H2694–703.
White, R. E., & Carrier, G. O. (1990). Vascular contraction induced by activation of membrane calcium ion channels is enhanced in streptozotocin-diabetes. Journal of Pharmacology and Experimental Therapeutics, 253, 1057–1062.
Whiteley, L., Padmanabhan, S., Hole, D., & Isles, C. (2005). Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care, 28, 1588–1593.
Xavier, F. E., Davel, A. P. C., Rossoni, L. V., & Vassallo, D. V. (2003). Time-dependent hyperreactivity to phenylephrine in aorta from untreated diabetic rats: Role of prostanoids and calcium mobilization. Vascular Pharmacology, 40, 67–76.
Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson, G. S., Takagi, H., Newsome, W. P., Jirousek, M. R., & King, G. L. (1996). Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. Journal of Clinical Investigation, 98, 2018–2026.
Yamada, Y., & Yokota, M. (1997). Effects of protein kinase C activation and inhibition on endothelin-1 release from human aortic and pulmonary artery endothelial cells comparison with effects on bovine endothelin-1 and human prostaglandin I2 release. American Journal of Hypertension, 10, 32–42.
Zimmet, P. Z. (2011). The growing pandemic of type 2 diabetes: A crucial need for prevention and improved detection. Medicographia, 33, 15–21.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
